{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:55Z","timestamp":1792461115985,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12064-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:16:20Z","timestamp":1766049380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18\u201330-year-old Chinese women: a phase III, double-blind, randomized, controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Liwei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HPV1003 Study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Li Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ke Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Min Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ya-Lin Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ling-Yun Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Xue-Mei Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Jing-Jing Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Wei Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Zi-Long Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Zhen Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Yu-Liang Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Rong-Cheng Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Yan-Ping Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nian-Min Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Qiang Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bin He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Shi-Fang Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Dong-Zhang Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Guo-Gang Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Yan-Xia Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Wei-Jiang Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Jiang-Bing Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Zhan-Bo Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Yan-Hua Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Yong-Biao Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Hai-Song Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"6","key":"12064_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, de Sanjos\u00e9 S, Herrero R, Castellsagu\u00e9 X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518\u201327. https:\/\/doi.org\/10.1056\/NEJMoa021641.","journal-title":"N Engl J Med"},{"key":"12064_CR2","unstructured":"Bruni L, Albero G, Serrano B, Mena M, G\u00f3mez D, Mu\u00f1oz J, Bosch FX, de Sanjos\u00e9 S. Human papillomavirus and related diseases in the world. Summary Report 17 June 2019. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2019. Available from: https:\/\/www.hpvcentre.net\/statistics\/reports\/XWX.pdf. Accessed 6 2025."},{"key":"12064_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3760\/cma.j.cn431274-20210819-00911","volume":"23","author":"Cervical Cancer Prevention Committee of Guangdong Preventive Medicine Association","year":"2021","unstructured":"Cervical Cancer Prevention Committee of Guangdong Preventive Medicine Association. Guangdong expert consensus on HPV vaccine application to eliminate cervical cancer. J Chin Physician. 2021;23:1303\u201315. https:\/\/doi.org\/10.3760\/cma.j.cn431274-20210819-00911. Chinese.","journal-title":"J Chin Physician"},{"key":"12064_CR4","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization. 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107. Accessed 6 Mar 2025."},{"issue":"19","key":"12064_CR5","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2023.04.009","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Shi LW, Yu BW, et al. Safety and immunogenicity of a Pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9\u201345 years: a randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine. 2023;41(19):3141\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.009.","journal-title":"Vaccine"},{"key":"12064_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2209001","author":"LW Shi","year":"2023","unstructured":"Shi LW, Li J, Yu BW, et al. Safety and immunogenicity of a bivalent HPV16\/18 vaccine in Chinese females. Hum Vaccin Immunother. 2023 2023 May 30;2209001. Epub ahead of print. https:\/\/doi.org\/10.1080\/21645515.2023.2209001.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"12064_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.037","volume":"23","author":"S Pagliusi","year":"2004","unstructured":"Pagliusi S, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23(5):569\u201378. https:\/\/doi.org\/10.1016\/j.vaccine.2004.07.037.","journal-title":"Vaccine"},{"key":"12064_CR8","volume-title":"WHO classification of tumours of female reproductive organs","year":"2014","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. WHO classification of tumours. Volume 6, 4th ed. Lyon: International Agency for Research on Cancer; 2014.","edition":"4"},{"issue":"1","key":"12064_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cam4.989","volume":"6","author":"FC Zhu","year":"2017","unstructured":"Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine in Chinese women aged 18\u201325 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017;6(1):12\u201325. https:\/\/doi.org\/10.1002\/cam4.989.","journal-title":"Cancer Med"},{"issue":"14","key":"12064_CR10","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1002\/cam4.2418","volume":"8","author":"FC Zhu","year":"2019","unstructured":"Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16\/18 vaccine in Chinese women aged 18\u201325 years: end-of-study results from a phase II\/III, randomised, controlled trial. Cancer Med. 2019;8(14):6195\u2013211. https:\/\/doi.org\/10.1002\/cam4.2418.","journal-title":"Cancer Med"},{"issue":"27","key":"12064_CR11","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.vaccine.2019.05.056","volume":"37","author":"L Wei","year":"2019","unstructured":"Wei L, Xie X, Liu J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2019;37(27):3617\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.056.","journal-title":"Vaccine"},{"issue":"2","key":"12064_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jnci\/djz074","volume":"112","author":"YL Qiao","year":"2020","unstructured":"Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145\u201353. https:\/\/doi.org\/10.1093\/jnci\/djz074.","journal-title":"J Natl Cancer Inst"},{"key":"12064_CR13","doi-asserted-by":"publisher","first-page":"CD009069","DOI":"10.1002\/14651858.CD009069.pub3","volume":"5","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069. https:\/\/doi.org\/10.1002\/14651858.CD009069.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"12064_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","volume":"1","author":"R Herrero","year":"2011","unstructured":"Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1(5):408\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0131.","journal-title":"Cancer Discov"},{"issue":"11","key":"12064_CR15","doi-asserted-by":"publisher","first-page":"e29184","DOI":"10.1002\/jmv.29184","volume":"95","author":"W Qu","year":"2023","unstructured":"Qu W, Sui L, Li Y. Vaccine escape challenges virus prevention: the example of two vaccine-preventable oncogenic viruses. J Med Virol. 2023;95(11):e29184.","journal-title":"J Med Virol"},{"key":"12064_CR16","volume-title":"Primary end-points for prophylactic HPV vaccine trials","author":"International Agency for Research on Cancer","year":"2014","unstructured":"International Agency for Research on Cancer. Primary end-points for prophylactic HPV vaccine trials. Lyon: IARC; 2014."},{"issue":"48","key":"12064_CR17","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1016\/j.vaccine.2023.10.063","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Shi LW, Li K, et al. Comparison of the safety and persistence of immunogenicity of bivalent HPV16\/18 vaccine in healthy 9\u201314-year-old and 18\u201326-year-old Chinese females: a randomized, double-blind, non-inferiority clinical trial. Vaccine. 2023;41(48):7212\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.063.","journal-title":"Vaccine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12064-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:06:24Z","timestamp":1770199584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12064-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12064"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12064-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Ethics Committee of the Guangxi Zhuang Autonomous Region CDC and from the ethics committees of all other participating centres; written informed consent was obtained from all participants prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}